News

Cyclo Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

Mar 10, 2022

Presentation with live video webcast on Wednesday, March 16th at 3:20 PM ET

GAINESVILLE, Fla. –
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 PM ET.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live video webcast of the virtual event will be available on the Events page of the Investors section of the Company’s website (cyclotherapeutics.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.

JTC Team, LLC

Jenene Thomas

(833) 475-8247

CYTH@jtcir.com

Our Pipeline
Our Science
Sign up for Alerts

Trappsol® Cyclo™ is not currently approved for any indication.

Third-party websites are provided for convenience only. Cyclo Therapeutics, Inc. does not approve of, or endorse any of the content. Cyclo Therapeutics, Inc. does not maintain, control or monitor the content of third-party websites in any way.